Use of Recommended Neurodiagnostic Evaluation Among Patients With Drug-Resistant Epilepsy.

Journal: JAMA neurology

Volume: 

Issue: 

Year of Publication: 

Affiliated Institutions:  Department of Biomedical Informatics, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York. Department of Neurological Surgery, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York. Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.

Abstract summary 

Interdisciplinary practice parameters recommend that patients with drug-resistant epilepsy (DRE) undergo comprehensive neurodiagnostic evaluation, including presurgical assessment. Reporting from specialized centers suggests long delays to referral and underuse of surgery; however, longitudinal data are limited to characterize neurodiagnostic evaluation among patients with DRE in more diverse US settings and populations.To examine the rate and factors associated with neurodiagnostic studies and comprehensive evaluation among patients with DRE within 3 US cohorts.A retrospective cross-sectional study was conducted using the Observational Medical Outcomes Partnership Common Data Model including US multistate Medicaid data, commercial claims data, and Columbia University Medical Center (CUMC) electronic health record data. Patients meeting a validated computable phenotype algorithm for DRE between January 1, 2015, and April 1, 2020, were included. No eligible participants were excluded.Demographic and clinical variables were queried.The proportion of patients receiving a composite proxy for comprehensive neurodiagnostic evaluation, including (1) magnetic resonance or other advanced brain imaging, (2) video electroencephalography, and (3) neuropsychological evaluation within 2 years of meeting the inclusion criteria.A total of 33 542 patients with DRE were included in the Medicaid cohort, 22 496 in the commercial insurance cohort, and 2741 in the CUMC database. A total of 31 516 patients (53.6%) were women. The proportion of patients meeting the comprehensive evaluation main outcome in the Medicaid cohort was 4.5% (n = 1520); in the commercial insurance cohort, 8.0% (n = 1796); and in the CUMC cohort, 14.3% (n = 393). Video electroencephalography (24.9% Medicaid, 28.4% commercial, 63.2% CUMC) and magnetic resonance imaging of the brain (35.6% Medicaid, 43.4% commercial, 52.6% CUMC) were performed more regularly than neuropsychological evaluation (13.0% Medicaid, 16.6% commercial, 19.2% CUMC) or advanced imaging (3.2% Medicaid, 5.4% commercial, 13.1% CUMC). Factors independently associated with greater odds of evaluation across all 3 data sets included the number of inpatient and outpatient nonemergency epilepsy visits and focal rather than generalized epilepsy.The findings of this study suggest there is a gap in the use of diagnostic studies to evaluate patients with DRE. Care setting, insurance type, frequency of nonemergency visits, and epilepsy type are all associated with evaluation. A common data model can be used to measure adherence with best practices across a variety of observational data sources.

Authors & Co-authors:  Spotnitz Ekanayake Ostropolets McKhann Choi Ottman Neugut Hripcsak Natarajan Youngerman

Study Outcome 

Source Link: Visit source

Statistics
Citations : 
Authors :  10
Identifiers
Doi : 10.1001/jamaneurol.2024.0551
SSN : 2168-6157
Study Population
Male,Female
Mesh Terms
Other Terms
Study Design
Study Approach
Country of Study
Publication Country
United States